Article
NAN Xiaoqiang, WANG Yanli, JIANG Xiaofan, LEI Peng, LI Juane
Objective To systematically evaluate the pharmacological effects and molecular mechanisms of Danlou
tablets with comprehensive pharmacological strategies, and to provide a theoretical basis for the treatment of diabetic
cardiomyopathy(DCM). Methods The chemical constituents and targets of Danlou tablets were discovered from the
platform of pharmacology analysis of traditional Chinese medicine system, and the interaction network of "componenttarget"
was established. All the targets of DCM were screened through the database, the relationship diagram of "componentdisease
target" was constructed. The core targets were screened, and the gene ontology analysis and the related pathway enrichment were performed on the core targets. The DCM rat model was treated with Danlou tablets to verify the predicted
important signaling pathways. Results A total of 190 compound nodes and 275 target nodes were screened from 10 important
formulations of Danlou tablet. A total of 19 targets related to DCM were screened from Danlou tablet, and 103 target related
pathways had role in DCM. In vivo, Danlou tablet reduced the expression of fibrosis-related factor messenger RNA in
myocardium of DCM rats and inhibited the expression of receptor for advanced glycation end products(RAGE)/nuclear
factor(NF)-κB/nucleotide-binding oligomerization domain-like receptor protein(NLRP)3 pathway-related proteins RAGE
and NLRP3, and phosphorylation of NF-κB(p65) protein. Conclusion Danlou tablets can inhibit myocardial fibrosis in
DCM rats by blocking the activation of RAGE/NF-κB/NLRP3 signaling pathway, and then inhibiting the progression of the
disease.